2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Pregnant, Young Adult
PAPER

2706 Real-world outcomes of GLP-1 receptor agonist therapy with survival, complications, and healthcare utilization in aplastic anemia

Asfand Yar Cheema, MD, Mishaal Munir, MD2, Himil Mahadevia, MBBS3, Mahmood Aldapt, M.B.B.S.4, Ali Mushtaq, MBBS5, Atulya Khosla, MBBS6, Aashray Mandala, BS7, Emily Wolf, MD8, Faiz Anwer, MD9, Marwan Shaikh, MD10
1 Mayo Clinic Florida, Jacksonville, Florida, United States
2 Miami Cancer Institute, Baptist health, Miami, Florida, United States
3 Mayo Clinic Florida, Jacksonville, Florida, United States
4 Mayo Clinic Florida, Jacksonville, Florida, United States
5 Mayo Clinic Florida, Jacksonville, Florida, United States
6 Mayo Clinic Florida, Jacksonville, Florida, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Mayo Clinic Florida, Jacksonville, Florida, United States
9 Mayo Clinic Florida, Jacksonville, Florida, United States
10 Mayo Clinic Florida, Jacksonville, Florida, United States
Introduction:
Aplastic anemia (AA) is an immune-mediated bone marrow failure syndrome characterized by pancytopenia, immune dysregulation, and hematopoietic stem cell depletion. Approximately 15% of patients with AA develop secondary myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) due to clonal evolution. Glucagon-like peptide-1 receptor agonists (GLP-1a), primarily indicated for glycemic control, have demonstrated anti-inflammatory and antineoplastic properties in preclinical studies through inhibition of the PI3K/AKT/mTOR, ERK/MAPK, NF-κB, and NLRP3 inflammasome pathways. These actions lead to reduced oxidative stress, cytokine suppression, and cell-cycle arrest, potentially mitigating immune-mediated marrow injury and limiting clonal progression in AA. Given these mechanistic insights, we evaluated the impact of GLP-1a therapy on clinical outcomes in patients with AA using a large real-world database.
Methods:
We conducted a retrospective, propensity score-matched (PSM) cohort study using the TriNetX Analytics Network database. Our analysis included Aplastic anemia patients with (n=1,726) and without (n=83,344) GLP-1a therapy between 2010 and 2022. PSM (1:1) was applied using a greedy nearest-neighbor method with a caliper of 0.1 pooled standard deviations, adjusting for demographics, AA-directed therapy, comorbidities, laboratory parameters, and cardiovascular medications. Primary outcomes were all-cause mortality, Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and venous thromboembolism (VTE). Secondary outcomes included hospitalizations, ICU admissions, acute kidney injury (AKI), and heart failure (HF). Outcomes were compared using odds ratios (ORs) with 95% confidence intervals (CIs) over a 3-year follow-up period.
Results:
After PSM, 1,669 matched pairs (mean age 57.4 ± 15.4 years for GLP-1a users and mean age 50.9 ± 20.3 years for non-users, male-to-female ratio 0.62) were analyzed. The mean duration of GLP-1a therapy among users was 268.33 ± 225.50 days. GLP-1a therapy was associated with significantly lower odds of all-cause mortality (OR 0.286, 95% (0.238, 0.345, p<0.001), MDS (OR 0.470, 95% CI 0.369, 0.599, p<0.001), AML (OR 0.393, 95% CI 0.276, 0.559, p<0.001),  ischemic stroke/TIA (OR 0.765, 95% CI 0.610, 0.961, p=0.021), and VTE (OR 0.540, 95% CI 0.444, 0.657, p<0.001). Additionally, GLP- 1a users demonstrated reduced odds of all-cause hospitalizations (OR 0.320, 95% CI 0.275, 0.373, p<0.001), ICU admissions (OR 0.319, 95% CI 0.266, 0.382, p<0.001), AKI (OR: 0.393, 95% CI: 0.339, 0.455,p <0.001), and HF (OR 0.548, 95% CI 0.471, 0.638, p<0.001)
Conclusion:
In this large, real-world, propensity-matched cohort study, GLP-1a therapy in AA patients was associated with significantly lower risks of all-cause mortality, MDS, AML, ischemic stroke/TIA, venous thromboembolism, and HF. GLP-1a use was also linked to reduced health care utilization, including all-cause hospitalizations and ICU admissions. While the observational nature and limited clinical granularity of the dataset preclude causal inference, these findings support a compelling rationale for prospective randomized controlled trials to evaluate GLP-1a as a disease-modifying adjunct in AA management.
Asfand Yar Cheema, MD: No relevant conflicts of interest to declare.